Weight loss drug Ozempic cuts depression, anxiety, and addiction risk
Why it matters: Ozempic's potential mental health benefits could transform treatment for obesity, diabetes, and co-occurring psychiatric conditions.
- GLP-1 medications, including semaglutide (Ozempic), are linked to a 42% reduction in psychiatric-related hospital visits and a 44% lower risk of depression.
- Users of semaglutide experienced a 38% decrease in anxiety disorders and a 47% reduction in substance use disorders, alongside a lower risk of suicidal behavior.
- Researchers suspect these mental health benefits stem from a combination of lifestyle improvements due to weight loss and direct effects of the medication on the brain, building on earlier findings about reduced alcohol use disorder.
- The study analyzed data from nearly 100,000 individuals in Swedish national health registers, including over 20,000 GLP-1 users, from 2009 to 2022.
New research from the University of Eastern Finland, Karolinska Institutet, and Griffith University reveals that GLP-1 medications like Ozempic, primarily known for weight loss and diabetes management, may significantly reduce the risk of depression, anxiety, and substance use disorders. The large-scale study observed substantial drops in psychiatric-related hospital visits and improved mental health outcomes among users, suggesting both lifestyle improvements and direct brain effects could be at play.
